JHJendrik Hardes

Jendrik Hardes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jendrik Hardes has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • What Is the Implant Survivorship and Functional Outcome After Total Humeral Replacement in Patients with Primary Bone Tumors?

    by Kristian Nikolaus Schneider, Jan Niklas Bröking, Georg Gosheger, Timo Lübben, Jendrik Hardes, Dominik Schorn, Maria Anna Smolle, Christoph Theil, Dimosthenis Andreou

    Background: Total humeral replacement is an option to reconstruct massive bone defects after resection of locally advanced bone tumors of the humerus. However, implant survivorship, potential risk factors for implant revision surgery, and functional results of total humeral replacement are poorly elucidated because of the rarity of the procedure. Questions/purposes: We asked: (1) What is the revision-free implant and overall limb survivorship after total humerus replacement? (2) What factors are associated with implant revision surgery? (3) What is the functional outcome of the procedure as determined by the Musculoskeletal Tumor Society (MSTS) score and the American Shoulder and Elbow Surgeons (ASES) score? Methods: Between August 1999 and December 2018, 666 patients underwent megaprosthetic reconstruction after resection of a primary malignant or locally aggressive/rarely metastasizing tumor of the long bones at our department. In all, 23% (154) of these patients had a primary tumor located in the humerus. During the study, we performed total humeral replacement in all patients with a locally advanced sarcoma, in patients with pathological fractures, in patients with skip metastases, or in patients with previous intralesional contaminating surgery, who would have no sufficient bone stock for a stable implant fixation for a single joint megaprosthetic replacement of the proximal or distal humerus. We performed no biological reconstructions or reconstructions with allograft-prosthetic composites. As a result, 5% (33 of 666) of patients underwent total humerus replacement. Six percent (2 of 33) of patients were excluded because they received a custom-made, three-dimensionally (3-D) printed hemiprosthesis, leaving 5% (31) of the initial 666 patients for inclusion in our retrospective analysis. Of these, 6% (2 of 31) had surgery more than 5 years ago, but they had not been seen in the last 5 years. Median (interquartile range) age at the time of surgery was 15 years (14 to 25 years), and indications for total humeral replacement were primary malignant bone tumors (n = 30) and a recurring, rarely metastasizing bone tumor (n = 1). All megaprosthetic reconstructions were performed with a single modular system. The implanted prostheses were silver-coated beginning in 2006, and beginning in 2010, a reverse proximal humerus component was used when appropriate. We analyzed endoprosthetic complications descriptively and assessed the functional outcome of all surviving patients who did not undergo secondary amputation using the 1993 MSTS score and the ASES score. The median (IQR) follow-up in all survivors was 75 months (50 to 122 months), with a minimum follow-up period of 25 months. We evaluated the following factors for possible association with implant revision surgery: age, BMI, reconstruction length, duration of surgery, extraarticular resection, pathological fracture, previous intralesional surgery, (neo-)adjuvant radio- and chemotherapy, and metastatic disease. Results: The revision-free implant survivorship at 1 year was 77% (95% confidence interval 58% to 89%) and 74% (95% CI 55% to 86%) at 5 years. The overall limb survivorship was 93% (95% CI 75% to 98%) after 1 and after 5 years. We found revision-free survivorship to be lower in patients with extraarticular shoulder resection compared with intraarticular resections (50% [95% CI 21% to 74%] versus 89% [95% CI 64% to 97%]) after 5 years (subhazard ratios for extraarticular resections 4.4 [95% CI 1.2 to 16.5]; p = 0.03). With the number of patients available for our analysis, we could not detect a difference in revision-free survivorship at 5 years between patients who underwent postoperative radiotherapy (40% [95% CI 5% to 75%]) and patients who did not (81% [95% CI 60% to 92%]; p = 0.09). The median (IQR) MSTS score in 9 of 13 surviving patients after a median follow-up of 75 months (51 to 148 months) was 87% (67% to 92%), and the median ASES score was 83 (63 to 89) of 100 points, with higher scores representing better function. Conclusion: Total humeral replacement after resection of locally advanced bone tumors appears to be associated with a good functional outcome in patients who do not die of their tumors, which in our study was approximately one- third of those who were treated with a resection and total humerus prosthesis. However, the probability of early prosthetic revision surgery is high, especially in patients undergoing extraarticular resections, who should be counseled accordingly. Still, our results suggest that if the prosthesis survives the first year, further risk for revision appears to be low. Future studies should reexamine the effect of postoperative radiotherapy on implant survival in a larger cohort and evaluate whether the use of soft tissue coverage with plastic reconstructive surgery might decrease the risk of early revisions, especially in patients undergoing extraarticular resections. Level of Evidence: Level III, therapeutic study.


  • Tumour endoprosthesis replacement in the proximal tibia after intra-articular knee resection in patients with sarcoma and recurrent giant cell tumour

    by Jendrik Hardes, Marcel-Philipp Henrichs, Georg Gosheger, Wiebke Guder, Markus Nottrott, Dimosthenis Andreou, Eike Bormann, Maria Eveslage, Gregor Hauschild, Arne Streitbürger

    Proximal tibia replacements are commonly associated with post-operative complications and poor functional results due to an insufficiency of the extensor mechanism.


  • Knochensarkome

    by Jendrik Hardes, Georg Gosheger, Timo Budny

    Knochensarkome sind im Gegensatz zu den häufig auftretenden benignen Knochentumoren und tumorähnlichen Knochenläsionen sehr selten und verursachen daher häufig diagnostische und therapeutische Schwierigkeiten. Dieser Beitrag hat zum Ziel, dem Leser die Diagnostik und zumeist multimodale Therapie der häufigsten Knochensarkome wie Osteosarkom, Ewing-Sarkom und Chondrosarkom näherzubringen. Bone sarcomas are extremely rare representing approximately 0.2% among all cancer types. Due to the rarity of these tumors both the patients and the physicians can overlook or misinterpret the first often unspecific symptoms of these tumors (pain, limping and swelling). Therefore, radiographic examination (X-ray and/or MRI) of the involved region in case of inexplicable symptoms is strongly recommended. The most common primary malignant bone tumor entity is osteosarcoma, followed by chondrosarcoma and Ewing sarcoma. Osteosarcomas and Ewing sarcomas occur predominantly in children, adolescents and young adults, while chondrosarcomas primarily affect older patients. Most of the tumors are located in the extremities and the pelvis and in about 90% of cases the surgical treatment can be performed by means of a limb-sparing wide resection. An endoprosthetic or biological reconstruction of the resulting defect, depending on several patient- und tumor-related factors, usually is necessary. Apart from the surgical treatment, patients with osteosarcoma and Ewing sarcoma require a pre- and postoperative chemotherapy, while Ewing sarcoma patients often undergo radiation therapy as well – in some cases as the only local therapy option. Regular follow-up examinations are required after the completion of treatment for the early detection and management of local and/or systemic recurrences. Diagnosis and therapy of these rare tumors must be obtained by an interdisciplinary approach for optimal patient care (i.e. oncologist, radiologists, pathologists, orthopaedic surgeons, radiotherapists). Without an interdisciplinary proceeding the risk of mistakes increases significantly, which can have grave consequences on the patients’ prognosis and functional outcome. Therefore, the centralized treatment of these patients in specialized sarcoma centres is recommended.


  • Open Access

    Eradication rates, risk factors, and implant selection in two-stage revision knee arthroplasty: a mid-term follow-up study

    by Steffen Hoell, Anna Sieweke, Georg Gosheger, Jendrik Hardes, Ralf Dieckmann, Helmut Ahrens, Arne Streitbuerger

    Two-stage revision (TSR) knee arthroplasty is an established treatment, but failure to control infection still occurs in 4–50 % of cases. The aim of this study was to assess the infection eradication rate, risk factors for failure, and the clinical outcome after two-stage revision knee arthroplasty. This retrospective study included 59 patients who had undergone at least one two-stage revision procedure due to periprosthetic joint infection (PJI). Demographic data, comorbidities, types of implant, and complications were analyzed. Univariate and multivariate logistic regression analysis were used to identify risk factors for failure. The infections were controlled in 55 patients (93.2 %). The follow-up period was 4.1 (±2.7) years. Infection control was achieved after the first TSR in 42 patients (71.2 %) and after the second TSR in 13 (76.5 %). The percentage of arthrodesis procedures in patients with infection control increased from 16.75 % after one TSR to 69.2 % after two TSRs. Multivariate logistic regression analysis identified body mass index (BMI) (odds ratio 1.22; 95 % confidence intervals, 1.07 to 1.40; p = 0.004) and smoking (OR 21.52; 95 % CI, 2.60 to 178.19; p = 0.004) as risk factors for failure. Two-stage revision protocols can achieve acceptable results even after a second procedure. It is still unclear whether the choice of implant influences failure rates. Risk factors for failure after two-stage revision were identified. Studies with larger sample sizes are needed in order to support these findings and identify further risk factors. To reduce failure rates, programs should be established to treat or minimize risk factors in patients with PJI.


  • Open Access

    Forequarter amputation: a safe rescue procedure in a curative and palliative setting in high-grade malignoma of the shoulder girdle

    by Ulrich Elsner, Marcel Henrichs, Georg Gosheger, Ralf Dieckmann, Markus Nottrott, Jendrik Hardes, Arne Streitbürger

    Forequarter amputation (FQA) is a surgical treatment of tumors in the upper extremity and shoulder girdle that infiltrate the neurovascular bundles. In both curative and palliative settings, FQA can serve as an effective oncological treatment. This study presents the FQA-related data of 30 patients (mean age 50 years) treated between 2000 and 2012. Their medical condition was high-grade bone or soft tissue sarcoma in 26 and high-grade carcinoma in four cases. Mean operation time was 119 min. One major and five minor complications occurred in the postoperative period. Resection margins were wide in 91 % of patients. Local recurrence was observed in four patients after 19 months on average. Patients treated with curative intention had a 5-year survival chance of 39 %. Average survival after palliative amputation was 11 months. FQA provides an opportunity for adequate oncological margins in large tumors, while offering relief from tumor-induced distress in palliative situations.


  • Knee salvage in revision arthroplasty after massive bone loss of the femur condyles (≥Engh III) with a single-modular-hinged knee revision implant

    by Arne Streitbuerger, Jendrik Hardes, Georg Gosheger, Ralf Dieckmann, Steffen Hoell

    Purpose Massive bone loss of the femur condyles in revision arthroplasty often requires modular-hinged revision implants to restore a stable joint situation. In the present series, the outcome after knee revision surgery using a single modular-hinged revision implant in patients with severe bone defects (>Engh III) is investigated. Methods Sixty patients with severe bone defects (≥Engh III) after failed primary and revision knee arthroplasty were included. Medium follow-up was 47 (range 10–84) months after knee revision surgery. Medium patient age was 70 (range 33–87) years at the time of surgery. An average of 2.3 prior knee operations per patient was performed. 70 % of the patients required the knee revision implant after two-stage revision because of a deep implant infection. Results Estimated 5 year extremity survival was 95 and 65 % implant survival. Reasons for implant revision in decreasing order were reinfection (30 %), aseptic loosening (13 %), and periprosthetic fracture (9.8 %). The average active range of motion in the knee joint was 88° (range 40°–115°) for flexion. An extension deficit of a mean of −6° was (range −50–5° hyper-extension) observed. Patient age influenced the functional results significantly in terms of reduced walking distances and decreased modified WOMAC score. Conclusion In consideration of this complex study, population acceptable functional results can be achieved using a modular knee revision endoprosthesis. In younger patients (<60 years), satisfying results in terms of walking ability and overall satisfactory can be expected. The outcome in older multimorbid patients is worse. Yet, operation in these patients can be feasible to restore enough mobility for daily household activities.


  • Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial.

    by Dimosthenis Andreou, Andreas Ranft, Daniel Baumhoer, Hendrik Van Den Berg, Bénédicte Brichard, P.D.Sander Dijkstra, Hans Gelderblom, Georg Gosheger, Jendrik Hardes, Wolfgang Hartmann, et al.

    11026 Background: Local recurrence (LR) is associated with very poor prognosis in ES patients. We sought to identify factors associated with LR in patients undergoing multimodal treatment. Methods: Retrospective analyses of the files of 1207 patients with previously untreated ES registered in the Euro-EWING99 trial (NCT00020566) from centers in D, A, B, CH, CZ und NL between 1998 and 2009. The primary outcome was local recurrence-free survival (LRFS), defined as the interval between diagnostic biopsy and LR. A secondary outcome was overall survival (OS). Results: With a median follow-up of 3.9 years for all patients and 5.9 years for survivors, LRFS was 81.6% at 5 years; OS was 59.9%. Pelvic tumors (PT) (p < 0.0001), primary tumor volume ≥ 200ml (p < 0.0001), locoregional tumor extension (p = 0.005), primary metastases (p < 0.0001), tumor regression ≤ 90% after neoadjuvant treatment (NT) (p < 0.0001) and deviations from protocol treatment (p = 0.001) were associated with a poorer LRFS. Complete removal of the involved bone was associated with improved LRFS (p = 0.007) and OS (p = 0.001) in PT, but not extremity tumors (ET) (p = 0.068; p = 0.848). Patients with PT undergoing surgery (S) and local radiation (RT) had an improved LRFS compared to patients undergoing only S (p = 0.01) or RT only (p < 0.0001). No differences in LRFS between S and S + RT were found in chest wall (CWT) (p = 0.239) and ET (p = 0.957); both provided better local control compared to RT only (p = 0.007 and p = 0.037 for CWT; p = 0.0002 and p = 0.001 for ET). PT with > 90% histological response to NT had a higher LRFS after S + RT compared to S only (p = 0.04) (n = 118), but not PT with ≤ 90% response (p = 0.564) (n = 38). Intralesional resections were associated with a poorer LRFS than marginal resections (p = 0.009), which had a poorer LRFS compared to wide or radical resections (p = 0.0002). Patients with soft tissue infiltration prior to surgery had a poorer LRFS (p = 0.001) and OS (p < 0.0001). Additional RT did not improve LRFS compared to S alone in these patients (p = 0.799). Conclusions: PT were associated with a poorer LRFS in this study, but appear to benefit from a complete removal of the involved bone and additional RT, even in cases with > 90% response to NT. RT additional to S does not appear to influence LRFS in CWT and ET.


  • Two-stage revision arthroplasty for periprosthetic joint infections: What is the value of cultures and white cell count in synovial fluid and CRP in serum before second stage reimplantation?

    by Steffen Hoell, Andrea Moeller, Georg Gosheger, Jendrik Hardes, Ralf Dieckmann, Dino Schulz

    Besides CRP in serum, white cell counts and cultures of synovial fluid are routinely used to detect periprosthetic joint infections. But the sensitivities of these parameters do vary from 12 to 100 %. In two stage revision arthroplasty before the second stage surgeons have to decide if reimplantation is justified. Therefore, we investigated the value of cultures and white cell count from the synovial fluid with a polymethyl methacrylate spacer in place and CRP in serum before reimplantation to detect persistent infection in a standardized setting. 115 patients with a two-stage revision hip or knee arthroplasty were included in this study. All patients had an antibiotic loaded polymethylmethacrylate spacer. Retrospectively synovial cultures, white blood count in synovial fluid and CRP in serum were assessed before reimplantation. The sensitivity of the synovial cultures was 5 % (95 % CI 0.13–24.87), with a specificity of 99 % (95 % CI 94.27–99.97). For white blood count in synovial fluid the sensitivity was 31.3 %, specificity was 39.1 %. Sensitivity for CRP in serum was 42.10 %, specificity was 84.21 %. Cultures from synovial fluid and white blood count in synovial fluid and CRP seem to be uncertain parameters to exclude persistent infection. We do not recommend joint aspiration before reimplantation anymore. Further research is necessary to find other markers to confirm or exclude persistent infection.


  • Open Access

    Analysis of surgical and oncological outcome in internal and external hemipelvectomy in 34 patients above the age of 65 years at a mean follow-up of 56 months

    by Wiebke K Guder, Jendrik Hardes, Georg Gosheger, Marcel-Philipp Henrichs, Markus Nottrott, Arne Streitbürger

    With an increasing life expectancy and improved treatment regimens for primary or secondary malignant diseases of soft tissue or bone, hemipelvectomy will have to be considered more often in elderly patients in the future. Scientific reviews concerned with the surgical and oncological outcome of elderly patients undergoing hemipelvectomy are scarce. Therefore, it is the purpose of this study to review the outcome of patients treated with that procedure at our hospital and investigate the feasibility of such extensive procedures at an increased age. A retrospective analysis of thirty-four patients who underwent hemipelvectomy at an age of 65 years or older was performed to determine their surgical and oncological outcome. The Kaplan-Meier method was used to calculate the cumulative probability of survival using the day of tumor resection as a starting point. Univariate analysis was carried out to investigate the influence of a particular single parameter. The mean age at operation was 70.2 years. Thirty patients were treated for intermediate- to high-grade sarcoma and 81.8% of tumors were larger than or equal to 10 cm in the longest diameter. Thirteen patients underwent internal hemipelvectomy and nine patients external hemipelvectomy as a primary procedure. Twelve patients were treated with external hemipelvectomy after failed local tumor control at primary operation. Wound infection occurred in 61.7% of cases. Three patients underwent amputation for non-manageable infection after internal hemipelvectomy. Hospital mortality was 8.8%. Clear resection margins were obtained in 88% of patients; in another 6% of patients planned intralesional resections were performed. Local recurrence occurred in 8.8% of patients at a mean time of 26 months after operation. Eleven patients are alive with no evidence of disease and 23 patients died of disease or other causes. Patients with pulmonary metastases had a mean survival period after operation to DOD of 22 months compared to 37 months in the curative group. Despite an elevated rate in hospital mortality and wound infection, this study suggests that hemipelvectomy is feasible in elderly patients, although requiring long hospitalization periods and causing a limited functional outcome.


  • Open Access

    Two-stage hip revision arthroplasty with a hexagonal modular cementless stem in cases of periprosthetic infection

    by Ralf Dieckmann, Dino Schulz, Georg Gosheger, Karsten Becker, Kiriakos Daniilidis, Arne Streitbürger, Jendrik Hardes, Steffen Hoell

    Two-stage revision arthroplasty is today regarded as the gold standard treatment method for deep prosthetic joint infection. The aim of the present study was to evaluate clinical and functional outcomes with the Modular Universal Tumor And Revision System (MUTARS) RS stem in patients undergoing two-stage revisions. The functional and clinical outcomes for 43 patients who had undergone two-stage revision procedures for PJI were analyzed in a retrospective study. The minimum follow-up period was 24 months. Shorter follow-up periods were only observed when there were complications such as loosening or recurrent infection. The mean follow-up period was 3.86 years (range 7 months to 11.6 years). The success rate with infection control for PJI was 93%. Reinfection occurred in four cases (7%). The risk of reinfection after MRSA infection was 20.5 times greater (P >0.01) than with sensitive or unknown bacteria. Two aseptic loosening occurred after 7 and 20 months. The average Harris Hip Score was 80 (range 62–93). This retrospective study showed a 93% rate of eradication using specific antibiotic therapy. With the modular MUTARS RS stem, there was a low rate of aseptic loosening of 4.6%. MRSA infection was identified as a risk factor for reinfection. The two-stage procedure with modular cementless implants used is therefore appropriate for treating periprosthetic infections associated with hip endoprostheses.